Immune-based therapies for treatment of HIV infection

Annals of Pharmacotherapy

Volumn 30, Issue 1, 1996, Pages 62-76

  Piscitelli, Stephen C ^a   Minor, James R ^b   Saville, M Wayne ^c,d   Davey Jr , Richard T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOTOXIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRALGIA; ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; FEVER; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOTHERAPY; INFLUENZA; KAPOSI SARCOMA; LYMPHOCYTE SUBPOPULATION; NEUTROPENIA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VIRUS REPLICATION;

EID: 0030039036     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000111     Document Type: Article

References (145)

1. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
2. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner Racz K, et al. Massive covert infection of helper T lymphocytes and macrophases by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
3. Davey RT Jr, Dewar RL, Reed GF, Vasudevachari MB, Polis MA, Kovacs JA, et al. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697.661. Proc Natl Acad Sci U S A 1993;90:5608-12.
4. Stein DS, Timpone JG, Gradon JD, Kagan JM, Schnittman SM. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual. Clin Infect Dis 1993;17:749-71.
5. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
6. Quinnan GV, Siegel JP, Epstein JS, Manischewitz JF, Barnes S, Wells MA. Mechanisms of T-cell functional deficiency in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:7104.
7. Winkelstein A, Kingsley LA, Klein RS, Lyter DW, Evans TL, Rinaldo CR, et al. Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection. Clin Exp Immunol 1988;71:417-22.
8. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV disease Biotherapy 1990;2:119-36.
9. Rook AH, Masur H, Lane HC, Frederick W, Kashara T, Macher AM, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
10. Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J Biol Resp Mod 1984;3:475-82.
11. Mertelsmann R, Welte K, Sternberg C, O'Reilly R, Moore MAS, Clarkson BD, et al. Treatment of immunodeficiency with interleukm-2: initial exploration. J Biol Resp Mod 1984;3:483-90
12. Lane HC, Siegel JP, Rook AH, Masur H, Gelmann EP, Quinnan GV, et al. Use of interleukin-2 in patients with the acquired immunodeficiency syndrome. J Biol Resp Mod 1984;3:512-6.
13. Kern P, Toy J, Dietrich M. Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 1985,50:1-6.
14. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987,3:115-24
15. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J AIDS 1991;4:11-23.
16. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr. A phase I study of interferon-α 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994;169:981-9.
17. Kovacs JA, Baseler M, Dewar R, Vogel S, Davey RT Jr, Falloon J, et al. Increases in CD4+ lymphocytes with intermittent courses of continuous interleukin-2 infusions in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332.567-75.
18. Wood R, Montoya JG, Kundu SK, Schwartz DH, Mengan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993,167:519-25.
19. McMahon D, Armstrong JA, Huang XL, Rinaldo CR Jr, Gupta P, Whiteside TL, et al. A phase I study of subcutaneous interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994;8:59-66.
20. Davey RT Jr, Wells MJ, Piscitelli SC, Kovacs JA, Walker RE, Polis MA, et at. Subcutaneous adminstration of interleukin-2 in HIV-1 infected individuals (abstract). Clin Infect Dis 1994;19:610
21. Deresinski SC, Israelski DI, Frascino RJ, Joseph P, Galpin JE, Conant MA, et al Randomized multi-center comparison of treatment of HIV infected patients: activated CD8+ cells plus rIL-2 plus antiretroviral (AR) therapy vs rIL-2 plus AR therapy vs AR therapy alone (abstracts). The 2nd National Conference on Human Retroviruses. Washington DC, February 1, 1995.
22. Ramachandran RV, Katzenstein D, Merigan TC. Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. J Infect Dis 1994;170:1044-6.
23. Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, Kolitz JE, et al Pharmacokinetics of recombinant interleukin-2 in humans Cancer Res 1990;50:2009-17.
24. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
25. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo adminstration. J Immunol 1983;130:2203-8.
26. Ohnishi H, Chao JTY, Lin KKM, Lee H, Chu M. Role of the kidney in metabolic change of interleukin-2. Tumor Biol 1989;10:202-14.
27. Piscitelli SC, Kovacs JA, Vogel S, Metcalf JA, Baseler M, Lane HC. Decline in interleukin-2 concentrations during intravenous infusion in HIV-infected patients (abstract). 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 1994.
28. Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of teceleukin (recombinant interleukin-2) after intravenous or subcutaneous administration to patients with cancer. J Biol Resp Mod 1989,8:440-9.
29. Bocci V, Carraro F, Zeuli M, Naldini A, Calabresi F. The lymphatic route. VIII Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients. Biotherapy 1993;6:73-7.
30. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-γ. Ann Intern Med 1988;108:36-41.
31. Sauter NP, Atkins MB, Mier JW, Lechan RM. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-α therapy for metastatic carcinoma: a case report. Am J Med 1992;92:441-4.
32. Scheibenbogen C, Keilholz U, Pezzutto A, Hunstein W. Rheumatic disease following immunotherapy (letter). Ann Rheum Dis 1993;52:165.
33. Miles SA. Pathogenesis of human immunodeficiency virus-related Kaposi's sarcoma. Curr Opin Oncol 1992;4:875-82.
34. Ensoli B, Barillan G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev 1992;127:147-55.
35. Yang J, Hagan MK, Offerman MK. Induction of IL-6 gene expression in Kaposi's sarcoma. J Immunol 1994;152:943-55.
36. Cai J, Gill PS, Masood R, Chandrasoma P, Jung B, Law RE, Radka SF. Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol 1994;145:74-9.
37. Miles SA. Kaposi sarcoma: a cytokine-responsive neoplasia? In. Benz CC, Liu ET, eds. Oncogenes and tumor suppressor genes in human malignancies. Boston: Kluwer Academic Publishers, 1993:129-40
38. DeWitt R, Raasveld MHM, Ten Berge RJM, Van der Wouw PA, Bakker PJM, Veenhof CHN. Interleukin-6 concentrations in the serum of patients with AIDS-associated Kaposi's sarcoma during treatment with interferon-alpha. J Intern Med 1991;229:539-42.
39. Ammann AJ, Palladino MA, Volberding P, Adams D, Martin ML, Conant M. Tumor necrosis factor alpha and beta in acquired immunodeficiency syndrome and AIDS-related complex. J Clin Immunol 1987;7:481-5.
40. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4
41. Gill P, Puri PK. Interleukin-4 receptor expression on AIDS-related Kaposi's sarcoma cells and inhibition of tumor cell growth and cytokine production by IL-4 (abstract). Proc Annu Meet Am Assoc Cancer Res 1993;34:A1121.
42. Miles SA, Mitsuyasu R, LaFleur F, Ryback M, Kasden P, Suckow C, et al. Phase I/II trial of interleukin-4 in KS (abstract). Int Conf AIDS 1994;10:46.
43. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste-Amezaga M, et al. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
44. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
45. Trinchieri G Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
46. Manetti R, Parronchi P, Giudizi MG, Piccinni M-P, Maggi E, Trinchieri G. et al. Natural killer cell stimulatory factor (interleukin 12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-204.
47. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
48. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:353-60.
49. Clerici M, Shearer GM. A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-11.
50. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-65.
51. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
52. Gazzinelli RT, Giese NA, Morse HC III. In vivo treatment with interleukin-12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994;180:2199-208.
53. Kim JH, Loveland JE, Sitz KV, Ratio S, McLinden RJ, Burke D, et al. IL-7 and IL-12 differentially augment gp160-specific T-cell proliferation in HIV-infected, gp160-vaccinated patients (abstract). II National Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.
54. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993;82:2790-6.
55. Trinchieri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 1994;15:460-3.
56. Foli A, Saville M, Baseler M, Yarchoan R. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 1995;85:2114-23.
57. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-51.
58. de Waal Malefyt R, Haanen J, Spits H, Roncardo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
59. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D-H, et al. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992;89:1890-3.
60. Saville MW, Taga K, Foli A, Broder S, Tosato G, Yarchoan R. Interleukin-10 suppresses HIV-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood 1994;83:3591-9.
61. Montaner LJ, Griffin P, Gordon S. Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro. J Gen Virol 1994;75:3393-400.
62. Masood R, Lunardi-Iskandar Y, Moudgil T, Zhang Y, Law RE, Huang CL, et al. IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun 1994;202:374-83.
63. Weissman D, Poli G, Fauci A Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor α and interleukin 6 induction of virus. AIDS Res Hum Retro 1994;10:1199-206.
64. Gartner S, Markovitz P, Markovitz DM, Kaplan MH, Gallo RC. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-9.
65. Perno CF, Yarchoan R, Cooney DA, Hartmen NR, Gartner S, Popvic M, et al. Inhibition of human immunodeficiency virus (HIV- I/HTLV-IIIKa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine. and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111-25.
66. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, et al. Interleukin-6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor-α by transcriptional and post-transcriptional mechanisms. J Exp Med 1990;172:151-8.
67. Weissman D, Li Y, Barker T, Daucher J, Fauci A. Dendritic cells bind HIV to their surface and infect unstimulated CD4 positive T cells (abstract). II National Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.
68. Denis M, Ghadirian E. Interleukin 13 and interleukin 4 protect bronchoalveolar macrophages from productive infection with human immundeficiency virus type 1. AIDS Res Hum Retroviruses 1994;10:795-802.
69. Mikovits JA, Meyers AM, Ortaldo JR, Minty A, Caput D, Ferrara P, et al. IL-4 and IL-13 have overlapping but distinct effects on HIV production in monocytes. J Leukoc Biol 1994;56:340-6.
70. Rios A, Mansell PWA, Newell GR, Reuben JM, Hersh EM. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 1985;3:506-12.
71. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-51.
72. Lane HC, Feinberg J, Davey V, Deyton L, Baseler M, Manischewitz J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988;2:1218-22.
73. Volberding P, Valero R, Rothamn J, Gee G. Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann N Y Acad Sci 1984;437:439-46.
74. Gelmann EP, Preble OT, Steis R, Lane HC, Rook AH, Wesley M, et al. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immunodeficiency syndrome: clinical response and prognostic parameters. Am J Med 1985:78:737-41.
75. Groopman JE, Gottleib MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, et al. Recombinant alpha-2-interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-80.
76. Krown SE, Gold JWM, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, et al. Interferon alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1990;112:812-21.
77. Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-Reese J, et al A phase I study of recombinant interferon alpha 2a or human lymphoblastoid inierferon alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J AIDS 1991;4:1-10.
78. Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N. Interferon-alpha, zidovudine and granulocyte-macrophage colony stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-51.
79. Podzamczer P, Bolao F, Clotet B, Garcia P, Casanova A, Pagerols X, et al. Low-dose interferon-alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1993;233:247-53.
80. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, et al. Combined zidovudine and interferon alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Ann Intern Med 1989;111:280-7.
81. Hersh EM, Gutterman JU, Alexanian R, Yap HY, Buzder AU. Impaired in vitro interferon blastogenic and natural killer cell responses to viral stimulation in acquired immunodeficiency syndrome. Cancer Res 1985;45:406-10.
82. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994;24:205-19.
83. Dorr RT. Interferon-α in malignant and viral diseases Drugs 1993;45:177-211.
84. Sules E, Floris C, Sulis M, Zurrida S, Piro S, Pintus A, et al. Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug-addicted patients with AIDS-related Kaposi's sarcoma. Eur J Cancer Clin Oncol 1989;25:759-61
85. Dupuy J, Price M, Lynch G, Brace S, Schwartz M. Intralesional interferon-α and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 1993;28:966-72.
86. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B. et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus infection: a randomized, placebo-controlled trial. Ann Intern Med 1990;112:805-11
87. Interferon Alpha Study Group. A randomized, placebo-controlled trial of recombinant human interferon alpha 2a in patients with AIDS. J AIDS 1988;1:111-8.
88. Hartshorn KL, Vogt MW, Ting-Chao C, Blumberg RS, Byington R, Schooley RT, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant interferon-alpha. Antimicrob Agents Chemother 1987;31:168-72.
89. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, et al. Regulation of HIV-replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 1990;145:2669-76.
90. Frissen PHJ, van der Ende ME. Napel CHHT, Weigel HM, Schreij GS, Kaufmann RH, et al. Zidovudine and interferon-α combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:1351-5.
91. Edlin BR, Weinstein RA, Whaling SM, Ou CY, Connolly PJ, Moore JL, et al. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type I infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. J Infect Dis 1992;165:793-8.
92. Koech DK, Obel AO, Minowada J, Hutchinson VA, Cummins JM. Low dose oral alpha-interferon for patients seropositive for human immunodeficiency virus type I. Mol Biother 1990;2:91-5.
93. Kaiser G, Jaeer H, Birkmann J, Poppinger J, Cummins JM, Gallmeier WM. Oral natural low dose human alpha-interferon in 29 patients with HIV-1 infection: a double-blind, randomized, placebo controlled trial. AIDS 1992;6:563-9.
94. Kim YW, Chang TW. Potential use of immunoconjugates for AIDS therapy. AIDS Res Hum Retroviruses 1992;8:1033-8.
95. Pincus SH. Immunotoxins: clinical potential in the treatment of AIDS. Clin Immunother 1994;1.89-94.
96. Ashorn P, Moss B, Weinstein JN, Chaudhary VK, Fitzgerald DJ, Pastan I, et al. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1990;87:8889-93.
97. Rubino KL, Tarpley WG, Nicholas JA. Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro. Antiviral Res 1991;16:267-79.
98. Ashorn P, Moss B, Berger EA. Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J AIDS 1992;5:70-7.
99. Davey RT Jr, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathem L, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994;170:1180-8.
100. Aukrust P, Liabakk KB, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
101. Kalinkovich A, Engelmann H, Harpaz N, Burstein R, Barak V, Kalick I, et al. Elevated serum levels of soluble tumor necrosis factor receptors in patients with HIV infection Clin Exp Immunol 1992;89:351-5.
102. Godfried MH, van der Poll T, Weverling GJ, Mulder JW, Jansen J, Van Deventer SJH, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169.739-45.
103. Mellors JW, Griffith BP, Ortiz MA. Tumor necrosis factor - alpha/ cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages J Infect Dis 1991;163:78-82.
104. Grunfeld C, Feingold KR. The role of cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992;122:749-53.
105. Grunfeld C, Feingold KR. Metabolic disturbances and washing in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:329-37.
106. Walker RE, Kelly GG, Kilgariff CE, Woody JN, Falloon J, Polis MA, et al. A pilot study of the safety and antiviral activity of a chimeric antibody in HIV infected patients (abstract). 34th Interscience Conference of Antimicrobial Agents and Chemotherapy. Orlando. FL, October 1994.
107. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1 Proc Natl Acad Sci U S A 1993;90:5974-8.
108. Ambrus JL, Lillie MA. Pentoxifylline in treatment of acquired immunodeficiency syndrome? Blood 1992;79:535-6.
109. Ghigliotti G, Repetto T, Farris A, Roy MT, DeMarchi R. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993;28(2 part 1):271-2.
110. Georghiou PR, Allworth AM. Thalidomide in painful AIDS-associated proctitis. J Infect Dis 1992;166:939-40.
111. Landman D, Sarai A, Sathe SS. Use of pentoxifyline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis 1994;18-97-9.
112. Bolognesi DP. The immune response to HIV: implications for vaccine development. Semin Immunol 1993;5:203-14.
113. Schwartz DH. Potential pitfalls on the road to an effective HIV vaccine. Immunol Today 1994;15:54-7.
114. Hoth DF. HIV vaccine development: a progress report. Ann Intern Med 1994;121:603-11.
115. Kovacs JA, Vasudevachari MB, Easter M, Davet RT, Falloon J, Polis MA, et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28.
116. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-30.
117. Sutjipto S, Pedersen NC, Miller CJ. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol 1990;64:2290-7.
118. Ezzell C. Clinical tests of first oral AIDS vaccine begin. J NIH Res 1994;6:65
119. Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol 1990;8:557-78.
120. Letvin ML. Nonhuman primate models for HIV vaccine development. Immunodef Rev 1992;3:247-60.
121. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS Cell 1991;65:651-62.
122. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attentuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-41.
123. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-25.
124. Desrosiers RC. Controversies in science: a live-virus AIDS vaccine? Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1. J NIH Res 1994;6:54-9.
125. Bolognesi DP. Controversies in science: a live-virus AIDS vaccine? Not yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1. J NIH Res 1994;6:55-62.
126. Essex M. The HIV-1 vaccine dilemma: lessons from the cat J NIH Res 1995;7:37-42.
127. Essex M Horizontally and vertically transmitted oncornavirus of cats. Adv Cancer Res 1975;21:175-248.
128. Clark N, Kushner NN, Barrett CB, Kensil KR, Salsbury D, Cotter S. Efficacy and safety field trials of a recombinant DNA virus vaccine against feline leukemia virus infection J Am Vet Med Assoc 1991;199:1433-43.
129. Zunich KM, Lane C, Davey RT, Falloon J, Polis M, Kovacs JA, et al. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals (abstract) AIDS Res Hum Retroviruses 1992,8:1335.
130. Redfield R, Birx D, Ketter N, Polonis V, Johnson S, Davis C, et al. Vaccine therapy using rgp160 in early HIV infection (abstract) AIDS Res Hum Retroviruses 1992;8:1333.
131. Esparza J, Osmanov S, Kallings LO, Wigzell H. Planning for HIV vaccine trials: the world. AIDS 1991;5(suppl 2):159-63.
132. Buchschacher GL. Molecular targets of gene transfer therapy for HIV infection. JAMA 1993;269:2880-6.
133. !33. Rohrbaugh ML, McGowan JJ. Gene transfer for therapy and prophylaxis of HIV-1 infection. Ann N Y Acad Sci 1993;685:697-712.
134. Sarver N, Rossi J. Gene therapy: a bold direction for HIV-1 treatment. AIDS Res Hum Retroviruses 1993;9:483-7.
135. Cotton P. High-tech assault on HIV: gene therapy. JAMA 1994;272:1235-6.
136. Bridges SH, Sarver N. Gene therapy and immune restoration for HIV disease. Lancet 1995;345:427-32.
137. Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A 1993;90:8000-4.
138. Curiel TJ, Cook DR, Wang Y, Hahn BH, Ghosh SK, Harrison GS. Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-upregulated diphtheria toxin A chain gene. Hum Gene Ther 1993;4:741-7.
139. Rossi JJ, Elkins D, Zaia JA, Sullivan S. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res Hum Retroviruses 1992;8:183-9.
140. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990;247:1222-5.
141. Barinaga M. Ribozymes: killing the messenger. Science 1993;262:1512-4.
142. Chang P, Cantin EM, Zaia JA. Ribozyme-mediated site-specific cleavage of the HIV-1 genome. Clin Biotechnol 1990;2:23-31.
143. Walker R, Blaese RM, Carter CS, Chang L, Klein H, Lane HC, et al. Clinical protocol: a study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. Hum Gene Ther 1993;4:659-80.
144. Afione SA, Conrad CK, Flotte TR. Gene therapy vectors as drag delivery systems. Clin Pharmacokinet 1995;28:181-9.
145. Thompson L. At age 2, gene therapy enters a growth phase. Science 1992;258:744-6.